- Home
- HBT vs SVRA Comparison
HBT vs SVRA Comparison
Compare HBT & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBT | SVRA |
|---|---|---|
| Founded | 1920 | 2007 |
| Country | United States | United States |
| Employees | 826 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2019 | 2009 |
Fundamental Metrics
Financial Performance| Metric | HBT | SVRA |
|---|---|---|
| Price | $32.18 | $6.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $30.75 | $7.33 |
| AVG Volume (30 Days) | 220.0K | ★ 2.0M |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | ★ 7.96 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.73 | N/A |
| Revenue Next Year | $7.01 | $430.87 |
| P/E Ratio | $96.29 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.36 | $2.14 |
| 52 Week High | $32.99 | $7.01 |
Technical Indicators
Market Signals| Indicator | HBT | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 68.51 | 70.02 |
| Support Level | $27.56 | $5.86 |
| Resistance Level | N/A | $6.49 |
| Average True Range (ATR) | 0.73 | 0.25 |
| MACD | 0.14 | 0.07 |
| Stochastic Oscillator | 74.51 | 90.83 |
Price Performance
Historical ComparisonAbout HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking. It generates revenue from Card income, Wealth management fees, and Service charges on deposit accounts.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).